IF 5.7 2区 医学 Q1 IMMUNOLOGY
Frontiers in Immunology Pub Date : 2025-03-19 eCollection Date: 2025-01-01 DOI:10.3389/fimmu.2025.1557790
Kaori Sakurai, Shotaro Chubachi, Jun Miyata, Junko Hamamoto, Tatsuro Naganuma, Takashi Shimada, Shiro Otake, Shingo Nakayama, Hidehiro Irie, Akihiro Tsutsumi, Naofumi Kameyama, Ahmed E Hegab, Masayuki Shimoda, Hideki Terai, Hiroyuki Yasuda, Yae Kanai, Makoto Arita, Koichi Fukunaga
{"title":"Celecoxib prevents malignant progression of smoking-induced lung tumors via suppression of the COX-2/PGE<sub>2</sub> signaling pathway in mice.","authors":"Kaori Sakurai, Shotaro Chubachi, Jun Miyata, Junko Hamamoto, Tatsuro Naganuma, Takashi Shimada, Shiro Otake, Shingo Nakayama, Hidehiro Irie, Akihiro Tsutsumi, Naofumi Kameyama, Ahmed E Hegab, Masayuki Shimoda, Hideki Terai, Hiroyuki Yasuda, Yae Kanai, Makoto Arita, Koichi Fukunaga","doi":"10.3389/fimmu.2025.1557790","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Lung cancer is characterized by a poor prognosis and is a significant comorbidity of chronic obstructive pulmonary disease (COPD). Therefore, effective chemopreventive agents are warranted. We evaluated the effects of the cyclooxygenase-2 (COX-2) inhibitor celecoxib on the prevention of lung-carcinoma development using an intermittent smoking-induced lung-carcinoma mouse model. Additionally, we explored COX-2's role in lipid metabolism.</p><p><strong>Methods: </strong>Male A/J mice were exposed to sham air or mainstream cigarette smoke for 20 weeks. Vehicle or celecoxib was administered via intragastric feeding once daily. Lung tissues were analyzed for tumor nodules and emphysema; the bronchoalveolar lavage fluid was collected for cell counting. COX-2 expression was measured using real-time polymerase chain reaction and western blotting; lipidomic analysis was conducted using liquid chromatography-tandem mass spectrometry. Cell proliferation and colony-forming assays were performed on LA-4 cells to assess the effects of prostaglandins and COX-2 inhibitors.</p><p><strong>Results: </strong>Intermittent smoking exposure increased lung adenomas, adenocarcinomas, and COX-2 expression. Lung adenomas were characterized by abundant COX-2-positive cells. Celecoxib reduced intermittent smoking-induced inflammation, emphysema, and cell counts in the bronchoalveolar lavage fluid and decreased the incidence of lung adenocarcinomas, whereas the total number of observed lung tumors was unchanged. Celecoxib markedly suppressed single-smoke-induced prostaglandin E2 (PGE<sub>2</sub>) production in the airway. PGE<sub>2</sub> increased LA-4 cell viability via the EP4 receptor and promoted colony formation.</p><p><strong>Discussion: </strong>Celecoxib effectively inhibited lung-carcinoma development, inflammation, and emphysema, demonstrating the potential for chemoprevention in smokers and patients with COPD. Further studies on EP4 inhibitors for the prevention of emphysema and lung cancer are warranted.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1557790"},"PeriodicalIF":5.7000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961424/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fimmu.2025.1557790","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介肺癌的特点是预后不良,是慢性阻塞性肺病(COPD)的重要合并症。因此,需要有效的化学预防药物。我们利用间歇性吸烟诱导的肺癌小鼠模型,评估了环氧化酶-2(COX-2)抑制剂塞来昔布对预防肺癌发生的作用。此外,我们还探讨了 COX-2 在脂质代谢中的作用:雄性 A/J 小鼠暴露于假空气或主流香烟烟雾中 20 周。每天一次通过胃内喂食给药剂或塞来昔布。分析肺组织中的肿瘤结节和肺气肿;收集支气管肺泡灌洗液进行细胞计数。采用实时聚合酶链反应和 Western 印迹法测定 COX-2 的表达;采用液相色谱-串联质谱法进行脂质体分析。对 LA-4 细胞进行了细胞增殖和集落形成试验,以评估前列腺素和 COX-2 抑制剂的作用:结果:间歇性吸烟增加了肺腺瘤、腺癌和 COX-2 的表达。肺腺瘤的特点是有大量 COX-2 阳性细胞。塞来昔布减少了间歇性吸烟引起的炎症、肺气肿和支气管肺泡灌洗液中的细胞数量,降低了肺腺癌的发病率,但观察到的肺肿瘤总数没有变化。塞来昔布显著抑制了单次吸烟诱导的气道前列腺素 E2(PGE2)的产生。PGE2通过EP4受体提高了LA-4细胞的活力,并促进了集落的形成:塞来昔布有效抑制了肺癌的发展、炎症和肺气肿,证明了其在吸烟者和慢性阻塞性肺病患者中的化学预防潜力。有必要进一步研究 EP4 抑制剂对肺气肿和肺癌的预防作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Celecoxib prevents malignant progression of smoking-induced lung tumors via suppression of the COX-2/PGE2 signaling pathway in mice.

Introduction: Lung cancer is characterized by a poor prognosis and is a significant comorbidity of chronic obstructive pulmonary disease (COPD). Therefore, effective chemopreventive agents are warranted. We evaluated the effects of the cyclooxygenase-2 (COX-2) inhibitor celecoxib on the prevention of lung-carcinoma development using an intermittent smoking-induced lung-carcinoma mouse model. Additionally, we explored COX-2's role in lipid metabolism.

Methods: Male A/J mice were exposed to sham air or mainstream cigarette smoke for 20 weeks. Vehicle or celecoxib was administered via intragastric feeding once daily. Lung tissues were analyzed for tumor nodules and emphysema; the bronchoalveolar lavage fluid was collected for cell counting. COX-2 expression was measured using real-time polymerase chain reaction and western blotting; lipidomic analysis was conducted using liquid chromatography-tandem mass spectrometry. Cell proliferation and colony-forming assays were performed on LA-4 cells to assess the effects of prostaglandins and COX-2 inhibitors.

Results: Intermittent smoking exposure increased lung adenomas, adenocarcinomas, and COX-2 expression. Lung adenomas were characterized by abundant COX-2-positive cells. Celecoxib reduced intermittent smoking-induced inflammation, emphysema, and cell counts in the bronchoalveolar lavage fluid and decreased the incidence of lung adenocarcinomas, whereas the total number of observed lung tumors was unchanged. Celecoxib markedly suppressed single-smoke-induced prostaglandin E2 (PGE2) production in the airway. PGE2 increased LA-4 cell viability via the EP4 receptor and promoted colony formation.

Discussion: Celecoxib effectively inhibited lung-carcinoma development, inflammation, and emphysema, demonstrating the potential for chemoprevention in smokers and patients with COPD. Further studies on EP4 inhibitors for the prevention of emphysema and lung cancer are warranted.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
9.80
自引率
11.00%
发文量
7153
审稿时长
14 weeks
期刊介绍: Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. Frontiers in Immunology is the official Journal of the International Union of Immunological Societies (IUIS). Encompassing the entire field of Immunology, this journal welcomes papers that investigate basic mechanisms of immune system development and function, with a particular emphasis given to the description of the clinical and immunological phenotype of human immune disorders, and on the definition of their molecular basis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信